Mesenchymal stem cell transplantation in the treatment of type 1 diabetic patients

Autologous mesenchymal stem cell transplantation in the treatment of type 1 diabetic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138810271414N8

Enrollment

Registered

2010-04-06

Start date

2010-01-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 diabetes. Insulin-dependent diabetes mellitus

Interventions

autologous mesenchymal stem cell transplantation.

Treatment - Other

autologous mesenchymal stem cell transplantation

Eligibility

Sex/Gender

All

Age

5 Years to 30 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: signing informed consent, presence of type 1 diabetes, age 5-30 years, duration of diabetes up to 20 weeks, being in stages before the onset of severe irreversible complications Exclusion criteria: history of DKA presentation, having acute infectious diseases

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
CD markers. Timepoint: 3 months. Method of measurement: serum analysis.;Anti insulin Ab. Timepoint: 3 months. Method of measurement: serum analysis.;Anti receptor Ab. Timepoint: 3 months. Method of measurement: serum analysis.;Anti GAD. Timepoint: 3 months. Method of measurement: serum analysis.;C-peptide. Timepoint: 3 months. Method of measurement: serum analysis.;HbA1c. Timepoint: 3 months. Method of measurement: blood sample analysis.;Insulin dose. Timepoint: 3 months. Method of measurement: mean dose of insulin injected in one week.;Mean of FBS. Timepoint: 3 months. Method of measurement: blood sample.;Mean of BS. Timepoint: 3 months. Method of measurement: blood sample.	—

Measure

Time frame

CD markers. Timepoint: 3 months. Method of measurement: serum analysis.;Anti insulin Ab. Timepoint: 3 months. Method of measurement: serum analysis.;Anti receptor Ab. Timepoint: 3 months. Method of measurement: serum analysis.;Anti GAD. Timepoint: 3 months. Method of measurement: serum analysis.;C-peptide. Timepoint: 3 months. Method of measurement: serum analysis.;HbA1c. Timepoint: 3 months. Method of measurement: blood sample analysis.;Insulin dose. Timepoint: 3 months. Method of measurement: mean dose of insulin injected in one week.;Mean of FBS. Timepoint: 3 months. Method of measurement: blood sample.;Mean of BS. Timepoint: 3 months. Method of measurement: blood sample.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 24, 2026